Investment Stage

Focus Areas

About Investor

David Schenkein is a general partner at GV, where he co-leads the life sciences investment team. His investing focus spans therapeutics, diagnostics, medical devices, novel care delivery systems, and payer innovation, and GV says it supports founders at every stage of company-building while Signal lists an investment range of $250K - $50.0M. Before joining GV, he spent a decade as CEO of Agios Pharmaceuticals, served as senior vice president of clinical hematology/oncology at Genentech, and earlier oversaw the clinical development and worldwide approval of Velcade at Millennium Pharmaceuticals.